Answers are grounded in this paper and cite their sources.
C-reactive protein (CRP) remains the most widely used inflammatory biomarker in clinical practice, valued for its assay standardization, low cost, and extensive validation. However, CRP is a systemic, hepatically derived marker that typically peaks 24–48 h after an inflammatory stimulus and does not capture localized, tissue-level inflammatory activity. Pentraxin 3 (PTX3), a long pentraxin produced locally by endothelial cells, macrophages, and other stromal cells, rises within 6–8 h of an inflammatory trigger and may provide complementary, tissue-specific information in selected clinical contexts. This narrative review searched PubMed, Scopus, and Web of Science for studies published between January 2014 and March 2026 using combinations of the terms “pentraxin 3,” “PTX3,” and “C-reactive protein”; 15 studies met the inclusion criteria after a structured screening process. Across the reviewed literature, PTX3 showed an earlier peak and stronger associations with disease severity and mortality than CRP in specific settings, including acute coronary syndrome, sepsis, and selected neurological and pregnancy-related conditions, although the findings were not uniform across all patient subgroups, particularly between sexes. Rather than replacing CRP, PTX3 is best understood as a complementary biomarker whose value is realized within a tiered testing strategy, in which CRP remains the first-line test and PTX3 is reserved for defined high-risk or diagnostically ambiguous scenarios. The wider clinical adoption of PTX3 will require assay standardization; defined reference intervals, including sex-specific ranges; and cost-effectiveness data before it can be incorporated into routine practice.
No takes yet. Share an insight, caveat, or question.
Chandankhede et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: